May 23, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post

May 23, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 15, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post

May 13, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

May 13, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post

May 02, 2025

Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC

In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that heterogeneously dose-escalated radiotherapy guided by fluorodeoxygl...

The ASCO Post

April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

March 06, 2025

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

Based on a systematic review and meta-analysis, plasma circulating tumor DNA (ctDNA) kinetics was found to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCL...

The ASCO Post

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post